AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
20.63
+0.51 (+2.53%)
At close: 4:00PM EDT

20.50 -0.13 (-0.63%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close20.12
Open20.25
Bid20.45 x 1000
Ask20.50 x 800
Day's Range19.76 - 20.74
52 Week Range2.35 - 21.05
Volume10,216,956
Avg. Volume13,272,572
Market Cap6.064B
Beta (3Y Monthly)-0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • 4 Strong Stocks to Buy That Double As Big Takeover Targets
    InvestorPlaceyesterday

    4 Strong Stocks to Buy That Double As Big Takeover Targets

    One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.

  • ACCESSWIRE2 days ago

    These Biotech and Cannabis Stocks Have Skyrocketing Potential

    HENDERSON, NV / ACCESSWIRE / October 15, 2018 / A fascinating biotechnology firm PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the between late August and early September going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain of 1795% as of the close on Friday. PPCB may start receiving increased attention from the street at any moment. PPCB has a 52 week high of $0.77.

  • Is Amarin Corporation PLC a Buy?
    Motley Fool6 days ago

    Is Amarin Corporation PLC a Buy?

    This biotech stock is riding high after fantastic results for Vascepa. But can Amarin go even higher?

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: Amarin and Immunomedics

    NEW YORK, NY / ACCESSWIRE / October 12, 2018 / U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. S&P 500 Index decreased 2.06 percent to close at 2,728.37 and the Nasdaq Composite Index closed down 1.25 percent to close at 7,329.06. The market losses are “a reaction from investors finally realizing we are in a higher interest-rate environment, and given the elevated level of stocks, market participants were likely looking for a reason to sell,” said Charlie Ripley, senior investment strategist for Allianz Investment Management.

  • Amarin (AMRN) Stock Moves -1.51%: What You Should Know
    Zacks7 days ago

    Amarin (AMRN) Stock Moves -1.51%: What You Should Know

    In the latest trading session, Amarin (AMRN) closed at $17.34, marking a -1.51% move from the previous day.

  • Why Amarin Stock Skyrocketed 415% in September
    Motley Fool9 days ago

    Why Amarin Stock Skyrocketed 415% in September

    The Irish biotech company might have struck gold with its prescription fish oil capsule.

  • ACCESSWIRE13 days ago

    Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones ...

  • Amarin Targets an Underserved Segment in the Cardiovascular Space
    Market Realist13 days ago

    Amarin Targets an Underserved Segment in the Cardiovascular Space

    Amarin Corporation (AMRN) expects that more than 25% of adults in the United States suffer from cardiovascular risk factors other than cholesterol, such as elevated triglyceride levels and diabetes. According to Amarin’s investor presentation, almost 50 million–70 million adults in the United States have triglyceride levels of higher than 150 mg/dL (milligrams per deciliter) and thus are part of the at-risk patient pool. While a significant portion of these patients are on statin therapy, they require additional treatment in the form of lipid-modifying prescription drugs.

  • Vascepa May Prove a Solid Growth Driver for Amarin Corporation
    Market Realist13 days ago

    Vascepa May Prove a Solid Growth Driver for Amarin Corporation

    As per Amarin’s (AMRN) investor presentation, the company aims to position Vascepa as a new treatment paradigm in the cardiovascular space. Amarin estimates that 38 million people in the United States are currently being treated with statin therapies mainly to control cholesterol. The best-selling statin therapy, Pfizer’s (PFE) Lipitor, managed to earn almost $12 billion annually before the launch of its generic version.

  • Here’s Why Amarin Stock Rose Yesterday
    Market Realist13 days ago

    Here’s Why Amarin Stock Rose Yesterday

    The rise was mainly attributable to the company’s presentation at the Cantor Global Healthcare Brokers Conference just a few days after it released positive data from its REDUCE-IT study of Vascepa. Amarin has reported a YTD (year-to-date) return of 353.87%. Amarin has emerged as one of the best-performing biotechnology stocks in 2018.

  • ACCESSWIRE14 days ago

    Today's Research Reports on Trending Tickers: Amarin and Novavax

    NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Major U.S. markets closed up on Wednesday, with the Dow Jones hitting a record high for the 15th time this year on upbeat economic data. However, market gains ...

  • ACCESSWIRE14 days ago

    Why This Undiscovered Device Stock Could Be Worth 3x

    With a multi-billion dollar market opportunity, companies in the cardiac monitoring arena have been big wins in the public realm. IRhythm (IRTC) shares have gone from $12 to $90 since their IPO a few years ago, as they're growing quickly and addressing a big market with their unique Zio device, which monitors a patient's heartbeat for irregularities remotely. Biotricity (BTCY) is one of the more recent entrants here with their Bioflux cardiac monitor, and they're now planning on a second product called Biopatch that should open up the market even further.

  • Here's Why Amarin Corporation Jumped Again Today
    Motley Fool14 days ago

    Here's Why Amarin Corporation Jumped Again Today

    The company presented at a healthcare conference for the first time since announcing REDUCE-IT trial results in September.

  • 3 Stocks to Buy and Hold for Decades
    Motley Fool14 days ago

    3 Stocks to Buy and Hold for Decades

    Your key to rich returns could lie among these retailer, payment-processing, and biopharma stocks.

  • ACCESSWIRE15 days ago

    Biotech Market is Rolling and These Companies Need to Be on Your Radar

    HENDERSON, NV / ACCESSWIRE / October 2, 2018 / If you're an investor looking to make huge gains fast, Biotech and Cannabis stocks provide the best opportunity. Each market has a huge following of investors ...

  • 2 Healthcare Stocks That Soared in September: Can They Keep Climbing?
    Motley Fool16 days ago

    2 Healthcare Stocks That Soared in September: Can They Keep Climbing?

    Marijuana and fish oil sent this pair soaring last month, but can they keep climbing?

  • 5 Best Biotech Stocks to Buy In October
    Zacks16 days ago

    5 Best Biotech Stocks to Buy In October

    Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

  • ACCESSWIRE17 days ago

    Today's Research Reports on Trending Tickers: Viking Therapeutics and Amarin

    NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Major U.S. markets finished flat on Friday. For the third quarter, the S&P 500 Index jumped over 7 percent, its best quarter since 2013, while the Dow Jones ...

  • Motley Fool17 days ago

    How Big Could Amarin's Vascepa Be?

    Data from a highly anticipated trial shows a remarkable ability to reduce the risk of heart attack or stroke.

  • From Fish Oil to Miracle Drug: Weekend Edition
    Bloomberg19 days ago

    From Fish Oil to Miracle Drug: Weekend Edition

    Fish-Oil Heart Medicine Is the Rarest of Drug Breakthroughs — Max NisenWhen medical breakthroughs are announced, they often affect a surprisingly small number of people. Many new drugs these days are targeting rare diseases or niche patient groups, and their impact is further restricted by price.

  • Largest Insider Trades of the Week
    GuruFocus.com19 days ago

    Largest Insider Trades of the Week

    The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Warning! GuruFocus has detected 2 Warning Sign with INTC. The clinical-stage biopharmaceutical company has a market cap of $911 million.

  • Why Bojangles, Lions Gate Entertainment, and Amarin Jumped Today
    Motley Fool19 days ago

    Why Bojangles, Lions Gate Entertainment, and Amarin Jumped Today

    Find out how one company hurt by Hurricane Florence is bouncing back.

  • Why Amarin Is Rallying Over 10% (Again!) on Friday
    Motley Fool19 days ago

    Why Amarin Is Rallying Over 10% (Again!) on Friday

    Investor optimism continues to build following market-moving trial data earlier this week.

  • Amarin Is Poised for Solid Revenue Growth in Fiscal 2018
    Market Realist19 days ago

    Amarin Is Poised for Solid Revenue Growth in Fiscal 2018

    Amarin witnessed a 17% YoY rise in Vascepa product revenues in the second quarter due to a solid rise in prescriptions for the drug and improved productivity across the company. According to the company’s second-quarter conference call, Symphony Health Solutions and IQVIA estimated the rise in normalized Vascepa prescriptions the second quarter of 77,000 and 84,000, respectively, on a YoY basis.

  • Amarin: Analysts’ Recommendations and Target Price
    Market Realist19 days ago

    Amarin: Analysts’ Recommendations and Target Price

    Amarin (AMRN) is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting unmet demand in the cardiovascular space. The company has witnessed a dramatic rise in its share prices from $2.99 on September 21 to $13.45 on September 26 mainly due to the positive top-line results from the REDUCE-IT cardiovascular outcomes study announced on September 24. According to Amarin’s press release, the outcomes study evaluated the potential of VASCEPA in reducing the risk of cardiovascular events in patients with LDL-C levels controlled by statin therapy.